FINAL WEEK to apply for more than $1 million in award funding! Let us fund your CGT research; apply through Aug. 1.
The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
In Q2 2024:
RNA therapies for myelodysplastic syndrome and respiratory syncytial virus (RSV) were approved in the U.S.
76 gene therapy trials were initiated—a 25% increase since Q1
$266.3 million, an 11% increase over the previous quarter, was raised
Read the Full Report
Read all available reports from 2024.
Read all the landscape reports from 2023.
Read all the landscape reports from 2022.
Read all the reports from 2021 here.
September 23-24, 2024 | Washington, D.C.
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico